Centrient Pharmaceuticals acquires Astral SteriTech
Dutch drugmaker Centrient Pharmaceuticals, an antibiotics manufacturer wholly-owned by Bain Capital, has acquired Vadodara, India-based Astral SteriTech, a manufacturer in sterile antibiotic injectable finished dosage forms.
The acquisition of Astral SteriTech, financial terms of which have not been disclosed, will:
- Further strengthens Centrient Pharmaceuticals’ position as the global business-to-business industry leader in beta-lactam antibiotics;
- Astral SteriTech brings in-house manufacturing capabilities for high-quality sterile antibiotic powder injectable finished dosage forms with two US Food and Drug Administration-approved production lines; and
- With its broadened product portfolio now including sterile injectable semi-synthetic cephalosporin and semi-synthetic penicillin finished dosage forms, Centrient can further meet the needs of customers in these segments and become a preferred partner for customers
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze